PPARγ as a potential therapeutic target in pulmonary hypertension

Therapeutic Advances in Respiratory Disease

Volumn 4, Issue 3, 2010, Pages 143-160

  Sutliff, Roy L ^a,b   Kang, Bum Yong ^a,b   Hart, C Michael ^a,b  

^a ATLANTA VA MEDICAL CENTER   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

PPAR ; pulmonary hypertension

Indexed keywords

LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; MESSENGER RNA; NITROUS OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 3; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR; PROSTACYCLIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; ROSIGLITAZONE; THROMBOXANE SYNTHASE; UNCLASSIFIED DRUG;

ANIMAL; CELL PROLIFERATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; HUMAN; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PULMONARY HYPERTENSION; REVIEW; VASCULAR ENDOTHELIUM; VASOCONSTRICTION; AMINO TERMINAL SEQUENCE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE COURSE; DRUG MECHANISM; ENZYME ACTIVITY; HYPOXIA; INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; STEM CELL; SUMOYLATION; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ANIMALS; CELL PROLIFERATION; DRUG DELIVERY SYSTEMS; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION, PULMONARY; LIGANDS; PPAR GAMMA; VASOCONSTRICTION;

EID: 77953336937     PISSN: 17534658     EISSN: None     Source Type: Journal    
DOI: 10.1177/1753465809369619     Document Type: Review

References (163)

1. Adnot, S., Raffestin, B., Eddahibi, S., Braquet, P. and Chabrier, P.E. ( 1991) Loss of endothelium-dependent relaxant activity in the pulmonary circulation of rats exposed to chronic hypoxia. J Clin Invest 87: 155-162.
2. Ambasta, R.K., Kumar, P., Griendling, K.K., Schmidt, H.H., Busse, R. and Brandes, R.P. ( 2004) Direct interaction of the novel Nox proteins with p22phox is required for the formation of a functionally active NADPH oxidase. J Biol Chem 279: 45935-45941.
3. Ameshima, S., Golpon, H., Cool, C.D., Chan, D., Vandivier, R.W., Gardai, S.J. et al. (2003) Peroxisome proliferator-activated receptor gamma (PPARgamma) expression is decreased in pulmonary hypertension and affects endothelial cell growth. Circ Res 92: 1162-1169.
4. Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T. et al. (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275: 964-967.
5. Azuma, H., Ishikawa, M. and Sekizaki, S. ( 1986) Endothelium-dependent inhibition of platelet aggregation. Br J Pharmacol 88: 411-415.
6. Bakouboula, B., Morel, O., Faure, A., Zobairi, F., Jesel, L., Trinh, A. et al. (2008) Procoagulant membrane microparticles correlate with the severity of pulmonary arterial hypertension. Am J Respir Crit Care Med 177: 536-543.
7. Balabanian, K., Foussat, A., Dorfmuller, P., Durand-Gasselin, I., Capel, F., Bouchet-Delbos, L. et al. (2002) CX(3)C chemokine fractalkine in pulmonary arterial hypertension. Am J Respir Crit Care Med 165: 1419-1425.
8. Balasubramaniam, V., Le Cras, T.D., Ivy, D.D., Grover, T.R., Kinsella, J.P. and Abman, S.H. ( 2003) Role of platelet-derived growth factor in vascular remodeling during pulmonary hypertension in the ovine fetus. Am J Physiol Lung Cell Mol Physiol 284: L826-L833.
9. Bao, Y., Li, R., Jiang, J., Cai, B., Gao, J., Le, K. et al. (2008) Activation of peroxisome proliferator-activated receptor gamma inhibits endothelin-1-induced cardiac hypertrophy via the calcineurin/NFAT signaling pathway. Mol Cell Biochem 317: 189-196.
10. Barak, Y., Nelson, M.C., Ong, E.S., Jones, Y.Z., Ruiz-Lozano, P., Chien, K.R. et al. (1999) PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell 4: 585-595.
11. Bath, P.M., Hassall, D.G., Gladwin, A.M., Palmer, R.M. and Martin, J.F. ( 1991) Nitric oxide and prostacyclin. Divergence of inhibitory effects on monocyte chemotaxis and adhesion to endothelium in vitro. Arterioscler Thromb 11: 254-260.
12. Bedard, K. and Krause, K.H. ( 2007) The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 87: 245-313.
13. Braissant, O., Foufelle, F., Scotto, C., Dauca, M. and Wahli, W. ( 1996) Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha-beta, and -gamma in the adult rat. Endocrinology 137: 354-366.
14. Busconi, L. and Michel, T. ( 1993) Endothelial nitric oxide synthase. N-terminal myristoylation determines subcellular localization. J Biol Chem 268: 8410-8413.
15. Calnek, D.S., Mazzella, L., Roser, S., Roman, J. and Hart, C.M. ( 2003) Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol 23: 52-57.
16. Camp, H.S., Li, O., Wise, S.C., Hong, Y.H., Frankowski, C.L., Shen, X. et al. (2000) Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone. Diabetes 49: 539-547.
17. Champion, H.C., Bivalacqua, T.J., Greenberg, S.S., Giles, T.D., Hyman, A.L. and Kadowitz, P.J. ( 2002) Adenoviral gene transfer of endothelial nitric-oxide synthase (eNOS) partially restores normal pulmonary arterial pressure in eNOS-deficient mice. Proc Natl Acad Sci U S A 99: 13248-13253.
18. Channick, R.N., Newhart, J.W., Johnson, F.W., Williams, P.J., Auger, W.R., Fedullo, P.F. et al. (1996) Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: an ambulatory delivery system and initial clinical tests. Chest 109: 1545-1549.
19. Chen, K., Kirber, M.T., Xiao, H., Yang, Y. and Keaney Jr, J.F. ( 2008) Regulation of ROS signal transduction by NADPH oxidase 4 localization. J Cell Biol 181: 1129-1139.
20. Chen, Y., Jimenez, A.R. and Medh, J.D. ( 2006) Identification and regulation of novel PPAR-gamma splice variants in human THP-1 macrophages. Biochim Biophys Acta 1759: 32-43.
21. Christman, B.W., McPherson, C.D., Newman, J.H., King, G.A., Bernard, G.R., Groves, B.M. et al. (1992) An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 327: 70-75.
22. Cowan, K.N., Jones, P.L. and Rabinovitch, M. ( 2000) Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease. J Clin Invest 105: 21-34.
23. Coyle, A.T. and Kinsella, B.T. ( 2006) Synthetic peroxisome proliferator-activated receptor gamma agonists rosiglitazone and troglitazone suppress transcription by promoter 3 of the human thromboxane A2 receptor gene in human erythroleukemia cells. Biochem Pharmacol 71: 1308-1323.
24. Crossno Jr, J.T., Garat, C.V., Reusch, J.E., Morris, K.G., Dempsey, E.C., McMurtry, I.F. et al. (2007) Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling. Am J Physiol Lung Cell Mol Physiol 292: L885-L897.
25. Delerive, P., Martin-Nizard, F., Chinetti, G., Trottein, F., Fruchart, J.C., Najib, J. et al. (1999) Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 85: 394-402.
26. Dimmeler, S., Fleming, I., Fisslthaler, B., Hermann, C., Busse, R. and Zeiher, A.M. ( 1999) Activation of nitric oxide synthase in endothelial cells by Aktdependent phosphorylation. Nature 399: 601-605.
27. Djordjevic, T., BelAiba, R.S., Bonello, S., Pfeilschifter, J., Hess, J. and Gorlach, A. ( 2005) Human urotensin II is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells. Arterioscler Thromb Vasc Biol 25: 519-525.
28. Dorfmuller, P., Zarka, V., Durand-Gasselin, I., Monti, G., Balabanian, K., Garcia, G. et al. (2002) Chemokine RANTES in severe pulmonary arterial hypertension. Am J Respir Crit Care Med 165: 534-539.
29. Edwards, W.D. and Edwards, J.E. ( 1977) Clinical primary pulmonary hypertension: three pathologic types. Circulation 56: 884-888.
30. Ehara, N., Hasegawa, K., Ono, K., Kawamura, T., Iwai-Kanai, E., Morimoto, T. et al. (2004) Activators of PPARgamma antagonize protection of cardiac myocytes by endothelin-1. Biochem Biophys Res Commun 321: 345-349.
31. Fagan, K.A., Fouty, B.W., Tyler, R.C., Morris Jr, K.G., Hepler, L.K., Sato, K. et al. (1999) The pulmonary circulation of homozygous or heterozygous eNOS-null mice is hyperresponsive to mild hypoxia. J Clin Invest 103: 291-299.
32. Failli, P., De, F.R., Caligiuri, A., Gentilini, A., Romanelli, R.G., Marra, F. et al. (2000) Nitrovasodilators inhibit platelet-derived growth factor-induced proliferation and migration of activated human hepatic stellate cells. Gastroenterology 119: 479-492.
33. Falcetti, E., Flavell, D.M., Staels, B., Tinker, A., Haworth, S.G. and Clapp, L.H. ( 2007) IP receptor-dependent activation of PPARgamma by stable prostacyclin analogues. Biochem Biophys Res Commun 360: 821-827.
34. Fang, S., Sharma, R.V. and Bhalla, R.C. ( 1997) Endothelial nitric oxide synthase gene transfer inhibits platelet-derived growth factor-BB stimulated focal adhesion kinase and paxillin phosphorylation in vascular smooth muscle cells. Biochem Biophys Res Commun 236: 706-711.
35. Farrow, B. and Evers, B.M. ( 2003) Activation of PPARgamma increases PTEN expression in pancreatic cancer cells. Biochem Biophys Res Commun 301: 50-53.
36. Forman, B.M., Chen, J. and Evans, R.M. ( 1996) The peroxisome proliferator-activated receptors: ligands and activators. Ann N Y Acad Sci 804: 266-275.
37. Forman, B.M., Chen, J. and Evans, R.M. ( 1997) Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A 94: 4312-4317.
38. Frasch, H.F., Marshall, C. and Marshall, B.E. ( 1999) Endothelin-1 is elevated in monocrotaline pulmonary hypertension. Am J Physiol 276: L304-L310.
39. Fredriksson, L., Li, H. and Eriksson, U. ( 2004) The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev 15: 197-204.
40. Frisdal, E., Gest, V., Vieillard-Baron, A., Levame, M., Lepetit, H., Eddahibi, S. et al. (2001) Gelatinase expression in pulmonary arteries during experimental pulmonary hypertension. Eur Respir J 18: 838-845.
41. Fukunaga, Y., Itoh, H., Doi, K., Tanaka, T., Yamashita, J., Chun, T.H. et al. (2001) Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides. Atherosclerosis 158: 113-119.
42. Fulton, D., Gratton, J.P., McCabe, T.J., Fontana, J., Fujio, Y., Walsh, K. et al. (1999) Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 399: 597-601.
43. Galie, N., Manes, A., Negro, L., Palazzini, M., Bacchi-Reggiani, M.L. and Branzi, A. (2009) A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 30: 394-403.
44. Garcia-Cardena, G., Fan, R., Shah, V., Sorrentino, R., Cirino, G., Papapetropoulos, A. et al. (1998) Dynamic activation of endothelial nitric oxide synthase by Hsp90. Nature 392: 821-824.
45. Garg, U.C. and Hassid, A. ( 1989) Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 83: 1774-1777.
46. Gensch, C., Clever, Y.P., Werner, C., Hanhoun, M., Bohm, M. and Laufs, U. ( 2007) The PPAR-gamma agonist pioglitazone increases neoangiogenesis and prevents apoptosis of endothelial progenitor cells. Atherosclerosis 192: 67-74.
47. Geraci, M.W., Gao, B., Shepherd, D.C., Moore, M.D., Westcott, J.Y., Fagan, K.A. et al. (1999) Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. J Clin Invest 103: 1509-1515.
48. Gericke, A., Munson, M. and Ross, A.H. ( 2006) Regulation of the PTEN phosphatase. Gene 374: 1-9.
49. Ghofrani, H.A., Seeger, W. and Grimminger, F. ( 2005) Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 353: 1412-1413.
50. Giaid, A. and Saleh, D. ( 1995) Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 333: 214-221.
51. Goetze, S., Xi, X.P., Kawano, H., Gotlibowski, T., Fleck, E., Hsueh, W.A. et al. (1999) PPAR gamma-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells. J Cardiovasc Pharmacol 33: 798-806.
52. Griendling, K.K., Sorescu, D. and Ushio-Fukai, M. ( 2000) NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 86: 494-501.
53. Guignabert, C., Alvira, C.M., Alastalo, T.P., Sawada, H., Hansmann, G., Zhao, M. et al. (2009) Tie2-mediated loss of peroxisome proliferator-activated receptor{gamma} in mice causes PDGF-receptor {beta}-dependant pulmonary arterial muscularization. Am J Physiol Lung Cell Mol Physiol 297(6): L1082-L1090.
54. Gupta, R.A., Tan, J., Krause, W.F., Geraci, M.W., Willson, T.M., Dey, S.K. et al. (2000) Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci U S A 97: 13275-13280.
55. Han, S.W. and Roman, J. ( 2006) Fibronectin induces cell proliferation and inhibits apoptosis in human bronchial epithelial cells: pro-oncogenic effects mediated by PI3-kinase and NF-kappa B. Oncogene 25: 4341-4349.
56. Hansmann, G., de Jesus Perez, V.A., Alastalo, T.P., Alvira, C.M., Guignabert, C., Bekker, J.M. et al. (2008a) An antiproliferative BMP-2/PPARgamma/ apoE axis in human and murine SMCs and its role in pulmonary hypertension. J Clin Invest 118: 1846-1857.
57. Hansmann, G., Wagner, R.A., Schellong, S., Perez, V.A., Urashima, T., Wang, L. et al. (2007) Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation. Circulation 115: 1275-1284.
58. Hansmann, L., Groeger, S., von Wulffen, W., Bein, G. and Hackstein, H. ( 2008b) Human monocytes represent a competitive source of interferon-alpha in peripheral blood. Clin Immunol 127: 252-264.
59. Hao, G.H., Niu, X.L., Gao, D.F., Wei, J. and Wang, N.P. ( 2008) Agonists at PPAR-gamma suppress angiotensin II-induced production of plasminogen activator inhibitor-1 and extracellular matrix in rat cardiac fibroblasts. Br J Pharmacol 153: 1409-1419.
60. Hassoun, P.M., Mouthon, L., Barbera, J.A., Eddahibi, S., Flores, S.C., Grimminger, F. et al. (2009) Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 54(1 Suppl): S10-S19.
61. Hill, J.M., Zalos, G., Halcox, J.P., Schenke, W.H., Waclawiw, M.A., Quyyumi, A.A. et al. (2003) Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348: 593-600.
62. Himelstein, B.P. and Koch, C.J. ( 1998) Studies of type IV collagenase regulation by hypoxia. Cancer Lett 124: 127-133.
63. Hoeper, M.M. ( 2009) The new definition of pulmonary hypertension. Eur Respir J 34: 790-791.
64. Hontecillas, R. and Bassaganya-Riera, J. ( 2007) Peroxisome proliferator-activated receptor gamma is required for regulatory CD4+ T cell-mediated protection against colitis. J Immunol 178: 2940-2949.
65. Hoshikawa, Y., Voelkel, N.F., Gesell, T.L., Moore, M.D., Morris, K.G., Alger, L.A. et al. (2001) Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling. Am J Respir Crit Care Med 164: 314-318.
66. Huang, J. and Kontos, C.D. ( 2002) Inhibition of vascular smooth muscle cell proliferation, migration, and survival by the tumor suppressor protein PTEN. Arterioscler Thromb Vasc Biol 22: 745-751.
67. Huang, J., Niu, X.L., Pippen, A.M., Annex, B.H. and Kontos, C.D. ( 2005) Adenovirus-mediated intraarterial delivery of PTEN inhibits neointimal hyperplasia. Arterioscler Thromb Vasc Biol 25: 354-358.
68. Humbert, M., Morrell, N.W., Archer, S.L., Stenmark, K.R., MacLean, M.R., Lang, I.M. et al. (2004) Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43(12 Suppl S): 13S-24S.
69. Hwang, J., Kleinhenz, D.J., Lassegue, B., Griendling, K.K., Dikalov, S. and Hart, C.M. ( 2005) Peroxisome proliferator-activated receptor-gamma ligands regulate endothelial membrane superoxide production. Am J Physiol Cell Physiol 288: C899-C905.
70. Hyduk, A., Croft, J.B., Ayala, C., Zheng, K., Zheng, Z.J. and Mensah, G.A. ( 2005) Pulmonary hypertension surveillance-United States, 1980-2002. MMWR Surveill Summ 54: 1-28.
71. Iglarz, M., Touyz, R.M., Amiri, F., Lavoie, M.F., Diep, Q.N. and Schiffrin, E.L. ( 2003a) Effect of peroxisome proliferator-activated receptor-alpha and- gamma activators on vascular remodeling in endothelin-dependent hypertension. Arterioscler Thromb Vasc Biol 23: 45-51.
72. Iglarz, M., Touyz, R.M., Viel, E.C., Paradis, P., Amiri, F., Diep, Q.N. et al. (2003b) Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoiddependent hypertension. Hypertension 42: 737-743.
73. Ikeda, Y., Sugawara, A., Taniyama, Y., Uruno, A., Igarashi, K., Arima, S. et al. (2000) Suppression of rat thromboxane synthase gene transcription by peroxisome proliferator-activated receptor gamma in macrophages via an interaction with NRF2. J Biol Chem 275: 33142-33150.
74. Issemann, I. and Green, S. ( 1990) Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347: 645-650.
75. Jeffery, T.K. and Morrell, N.W. ( 2002) Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension. Prog Cardiovasc Dis 45: 173-202.
76. Jernigan, N.L., Walker, B.R. and Resta, T.C. ( 2004) Endothelium-derived reactive oxygen species and endothelin-1 attenuate NO-dependent pulmonary vasodilation following chronic hypoxia. Am J Physiol Lung Cell Mol Physiol 287: L801-L808.
77. Kanki-Horimoto, S., Horimoto, H., Mieno, S., Kishida, K., Watanabe, F., Furuya, E. et al. (2006) Implantation of mesenchymal stem cells overexpressing endothelial nitric oxide synthase improves right ventricular impairments caused by pulmonary hypertension. Circulation 114(1 Suppl): 1181- 1185.
78. Kelly, D., Campbell, J.I., King, T.P., Grant, G., Jansson, E.A., Coutts, A.G. et al. (2004) Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nat Immunol 5: 104-112.
79. Kodera, Y., Takeyama, K., Murayama, A., Suzawa, M., Masuhiro, Y. and Kato, S. ( 2000) Ligand type-specific interactions of peroxisome proliferator-activated receptor gamma with transcriptional coactivators. J Biol Chem 275: 33201-33204.
80. Konduri, G.G., Ou, J., Shi, Y. and Pritchard Jr, K.A. ( 2003) Decreased association of HSP90 impairs endothelial nitric oxide synthase in fetal lambs with persistent pulmonary hypertension. Am J Physiol Heart Circ Physiol 285: H204-H211.
81. Kota, B.P., Huang, T.H. and Roufogalis, B.D. ( 2005) An overview on biological mechanisms of PPARs. Pharmacol Res 51: 85-94.
82. Kuzkaya, N., Weissmann, N., Harrison, D.G. and Dikalov, S. ( 2003) Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide synthase. J Biol Chem 278: 22546-22554.
83. Kwon, J., Lee, S.R., Yang, K.S., Ahn, Y., Kim, Y.J., Stadtman, E.R. et al. (2004) Reversible oxidation and inactivation of the tumor suppressor PTEN in cells stimulated with peptide growth factors. Proc Natl Acad Sci U S A 101: 16419-16424.
84. Lambeth, J.D. ( 2002) Nox/Duox family of nicotinamide adenine dinucleotide (phosphate) oxidases. Curr Opin Hematol 9: 11-17.
85. Lambeth, J.D., Kawahara, T. and Diebold, B. ( 2007) Regulation of Nox and Duox enzymatic activity and expression. Free Radic Biol Med 43: 319-331.
86. Laudet, V., Hanni, C., Coll, J., Catzeflis, F. and Stehelin, D. ( 1992) Evolution of the nuclear receptor gene superfamily. EMBO J 11: 1003-1013.
87. Law, R.E., Goetze, S., Xi, X.P., Jackson, S., Kawano, Y., Demer, L. et al. (2000) Expression and function of PPARgamma in rat and human vascular smooth muscle cells. Circulation 101: 1311-1318.
88. Lee, S.R., Yang, K.S., Kwon, J., Lee, C., Jeong, W. and Rhee, S.G. ( 2002) Reversible inactivation of the tumor suppressor PTEN by H2O2. J Biol Chem 277: 20336-20342.
89. Lepetit, H., Eddahibi, S., Fadel, E., Frisdal, E., Munaut, C., Noel, A. et al. (2005) Smooth muscle cell matrix metalloproteinases in idiopathic pulmonary arterial hypertension. Eur Respir J 25: 834-842.
90. Leslie, N.R., Bennett, D., Lindsay, Y.E., Stewart, H., Gray, A. and Downes, C.P. ( 2003) Redox regulation of PI 3-kinase signalling via inactivation of PTEN. Embo J 22: 5501-5510.
91. Li, H., Chen, S.J., Chen, Y.F., Meng, Q.C., Durand, J., Oparil, S. et al. (1994) Enhanced endothelin-1 and endothelin receptor gene expression in chronic hypoxia. J Appl Physiol 77: 1451-1459.
92. Lim, H. and Dey, S.K. ( 2002) A novel pathway of prostacyclin signaling-hanging out with nuclear receptors. Endocrinology 143: 3207-3210.
93. Liu, J.Q., Zelko, I.N., Erbynn, E.M., Sham, J.S. and Folz, R.J. ( 2006) Hypoxic pulmonary hypertension: role of superoxide and NADPH oxidase (gp91phox). Am J Physiol Lung Cell Mol Physiol 290: L2-L10.
94. Macchia, A., Marchioli, R., Marfisi, R., Scarano, M., Levantesi, G., Tavazzi, L. et al. (2007) A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J 153: 1037-1047.
95. Maehama, T. and Dixon, J.E. ( 1998) The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273: 13375-13378.
96. Makino, N., Sugano, M., Satoh, S., Oyama, J. and Maeda, T. ( 2006) Peroxisome proliferator-activated receptor-gamma ligands attenuate brain natriuretic peptide production and affect remodeling in cardiac fibroblasts in reoxygenation after hypoxia. Cell Biochem Biophys 44: 65-71.
97. Martin-Nizard, F., Furman, C., Delerive, P., Kandoussi, A., Fruchart, J.C., Staels, B. et al. (2002) Peroxisome proliferator-activated receptor activators inhibit oxidized low-density lipoprotein-induced endothelin-1 secretion in endothelial cells. J Cardiovasc Pharmacol 40: 822-831.
98. Marx, N., Schonbeck, U., Lazar, M.A., Libby, P. and Plutzky, J. ( 1998) Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 83: 1097-1103.
99. Matsuda, Y., Hoshikawa, Y., Ameshima, S., Suzuki, S., Okada, Y., Tabata, T. et al. (2005) Effects of peroxisome proliferator-activated receptor gamma ligands on monocrotaline-induced pulmonary hypertension in rats. Nihon Kokyuki Gakkai Zasshi 43: 283-288.
100. McQuillan, L.P., Leung, G.K., Marsden, P.A., Kostyk, S.K. and Kourembanas, S. ( 1994) Hypoxia inhibits expression of eNOS via transcriptional and posttranscriptional mechanisms. Am J Physiol 267: H1921-H1927.
101. Medoff, B.D., Okamoto, Y., Leyton, P., Weng, M., Sandall, B.P., Raher, M.J. et al. (2009) Adiponectin deficiency increases allergic airway inflammation and pulmonary vascular remodeling. Am J Respir Cell Mol Biol 41: 397-406.
102. Mehta, S., Stewart, D.J., Langleben, D. and Levy, R.D. ( 1995) Short-term pulmonary vasodilation with L-arginine in pulmonary hypertension. Circulation 92: 1539-1545.
103. Mittal, M., Roth, M., Konig, P., Hofmann, S., Dony, E., Goyal, P. et al. (2007) Hypoxia-dependent regulation of nonphagocytic NADPH oxidase subunit NOX4 in the pulmonary vasculature. Circ Res 101: 258-267.
104. Mizukami, J. and Taniguchi, T. ( 1997) The antidiabetic agent thiazolidinedione stimulates the interaction between PPAR gamma and CBP. Biochem Biophys Res Commun 240: 61-64.
105. Morrell, N.W., Adnot, S., Archer, S.L., Dupuis, J., Jones, P.L., MacLean, M.R. et al. (2009) Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol 54(1 Suppl): S20-S31.
106. Murata, T., Hori, M., Sakamoto, K., Karaki, H. and Ozaki, H. ( 2004) Dexamethasone blocks hypoxia-induced endothelial dysfunction in organ-cultured pulmonary arteries. Am J Respir Crit Care Med 170: 647-655.
107. Murata, T., Sato, K., Hori, M., Ozaki, H. and Karaki, H. ( 2002) Decreased endothelial nitric-oxide synthase (eNOS) activity resulting from abnormal interaction between eNOS and its regulatory proteins in hypoxia-induced pulmonary hypertension. J Biol Chem 277: 44085-44092.
108. Nagaya, N., Kangawa, K., Kanda, M., Uematsu, M., Horio, T., Fukuyama, N. et al. (2003) Hybrid cell-gene therapy for pulmonary hypertension based on phagocytosing action of endothelial progenitor cells. Circulation 108: 889-895.
109. Nemenoff, R., Meyer, A.M., Hudish, T.M., Mozer, A.B., Snee, A., Narumiya, S. et al. (2008) Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator-activated receptor gamma. Cancer Prev Res (Phila PA) 1: 349-356.
110. Nisbet, R.E., Bland, J.M., Kleinhenz, D.J., Mitchell, P.O., Walp, E.R., Sutliff, R.L. et al. (2009) Rosiglitazone attenuates chronic hypoxia-induced pulmonary hypertension in a mouse model. Am J Respir Cell Mol Biol 42(4): 482-490.
111. Novotna, J. and Herget, J. ( 2002) Possible role of matrix metalloproteinases in reconstruction of peripheral pulmonary arteries induced by hypoxia. Physiol Res 51: 323-334.
112. Olefsky, J.M. and Saltiel, A.R. ( 2000) PPAR gamma and the treatment of insulin resistance. Trends Endocrinol Metab 11: 362-368.
113. Olschewski, H., Rose, F., Schermuly, R., Ghofrani, H.A., Enke, B., Olschewski, A. et al. (2004) Prostacyclin and its analogues in the treatment of pulmonary hypertension. Pharmacol Ther 102: 139-153.
114. Ozaki, M., Kawashima, S., Yamashita, T., Ohashi, Y., Rikitake, Y., Inoue, N. et al. (2001) Reduced hypoxic pulmonary vascular remodeling by nitric oxide from the endothelium. Hypertension 37: 322-327.
115. Palmer, R.M., Ferrige, A.G. and Moncada, S. ( 1987) Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327: 524-526.
116. Pascual, G., Fong, A.L., Ogawa, S., Gamliel, A., Li, A.C., Perissi, V. et al. (2005) A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 437: 759-763.
117. Patel, L., Pass, I., Coxon, P., Downes, C.P., Smith, S.A. and Macphee, C.H. ( 2001) Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN. Curr Biol 11: 764-768.
118. Peng, Y., Liu, H., Liu, F., Liu, Y., Li, J. and Chen, X. ( 2006) Troglitazone inhibits synthesis of transforming growth factor-beta1 and reduces matrix production in human peritoneal mesothelial cells. Nephrology (Carlton) 11: 516-523.
119. Peredo, H.A., Mayer, M.A., Carranza, A. and Puyo, A.M. ( 2008) Pioglitazone and losartan modify hemodynamic and metabolic parameters and vascular prostanoids in fructose-overloaded rats. Clin Exp Hypertens 30: 159-169.
120. Pistrosch, F., Herbrig, K., Oelschlaegel, U., Richter, S., Passauer, J., Fischer, S. et al. (2005) PPARgammaagonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells. Atherosclerosis 183: 163-167.
121. Polikandriotis, J.A., Mazzella, L.J., Rupnow, H.L. and Hart, C.M. ( 2005) Peroxisome proliferator-activated receptor gamma ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor gamma-dependent mechanisms. Arterioscler Thromb Vasc Biol 25: 1810-1816.
122. Pritchard Jr, K.A., Ackerman, A.W., Gross, E.R., Stepp, D.W., Shi, Y., Fontana, J.T. et al. (2001) Heat shock protein 90 mediates the balance of nitric oxide and superoxide anion from endothelial nitric-oxide synthase. J Biol Chem 276: 17621-17624.
123. Rabinovitch, M. ( 2008) Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 118: 2372-2379.
124. Raines, E.W. ( 2004) PDGF and cardiovascular disease. Cytokine Growth Factor Rev 15: 237-254.
125. Robbins, I.M., Morrow, J.D. and Christman, B.W. ( 2005) Oxidant stress but not thromboxane decreases with epoprostenol therapy. Free Radic Biol Med 38: 568-574.
126. Rosenkranz-Weiss, P., Sessa, W.C., Milstien, S., Kaufman, S., Watson, C.A. and Pober, J.S. ( 1994) Regulation of nitric oxide synthesis by proinflammatory cytokines in human umbilical vein endothelial cells. Elevations in tetrahydrobiopterin levels enhance endothelial nitric oxide synthase specific activity. J Clin Invest 93: 2236-2243.
127. Rosenzweig, A. ( 2005) Circulating endothelial progenitors - cells as biomarkers. N Engl J Med 353: 1055-1057.
128. Sakai, S., Miyauchi, T., Irukayama-Tomobe, Y., Ogata, T., Goto, K. and Yamaguchi, I. ( 2002) Peroxisome proliferator-activated receptor-gamma activators inhibit endothelin-1-related cardiac hypertrophy in rats. Clin Sci (Lond) 103(Suppl 48): 16S-20S.
129. Sanchez, O., Marcos, E., Perros, F., Fadel, E., Tu, L., Humbert, M. et al. (2007) Role of endothelium-derived CC chemokine ligand 2 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 176: 1041-1047.
130. Sandirasegarane, L., Charles, R., Bourbon, N. and Kester, M. ( 2000) NO regulates PDGF-induced activation of PKB but not ERK in A7r5 cells: implications for vascular growth arrest. Am J Physiol Cell Physiol 279: C225-C235.
131. Sata, M. ( 2006) Role of circulating vascular progenitors in angiogenesis, vascular healing, and pulmonary hypertension: lessons from animal models. Arterioscler Thromb Vasc Biol 26: 1008-1014.
132. Satoh, K., Kagaya, Y., Nakano, M., Ito, Y., Ohta, J., Tada, H. et al. (2006) Important role of endogenous erythropoietin system in recruitment of endothelial progenitor cells in hypoxia-induced pulmonary hypertension in mice. Circulation 113: 1442-1450.
133. Schermuly, R.T., Dony, E., Ghofrani, H.A., Pullamsetti, S., Savai, R., Roth, M. et al. (2005) Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 115: 2811-2821.
134. Schwartzbauer, G. and Robbins, J. ( 2001) The tumor suppressor gene PTEN can regulate cardiac hypertrophy and survival. J Biol Chem 276: 35786-35793.
135. Serrander, L., Cartier, L., Bedard, K., Banfi, B., Lardy, B., Plastre, O. et al. (2007) NOX4 activity is determined by mRNA levels and reveals a unique pattern of ROS generation. Biochem J 406: 105-114.
136. Sessa, W.C., Garcia-Cardena, G., Liu, J., Keh, A., Pollock, J.S., Bradley, J. et al. (1995) The Golgi association of endothelial nitric oxide synthase is necessary for the efficient synthesis of nitric oxide. J Biol Chem 270: 17641-17644.
137. Simonneau, G., Robbins, I.M., Beghetti, M., Channick, R.N., Delcroix, M., Denton, C.P. et al. (2009) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54(1 Suppl): S43-S54.
138. Sorescu, D., Weiss, D., Lassegue, B., Clempus, R.E., Szocs, K., Sorescu, G.P. et al. (2002) Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation 105: 1429-1435.
139. Sorescu, G.P., Song, H., Tressel, S.L., Hwang, J., Dikalov, S., Smith, D.A. et al. (2004) Bone morphogenic protein 4 produced in endothelial cells by oscillatory shear stress induces monocyte adhesion by stimulating reactive oxygen species production from a nox1-based NADPH oxidase. Circ Res 95: 773-779.
140. Steinhorn, R.H., Russell, J.A., Lakshminrusimha, S., Gugino, S.F., Black, S.M. and Fineman, J.R. ( 2001) Altered endothelium-dependent relaxations in lambs with high pulmonary blood flow and pulmonary hypertension. Am J Physiol Heart Circ Physiol 280: H311-H317.
141. Stenmark, K.R., Fagan, K.A. and Frid, M.G. ( 2006) Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res 99: 675-691.
142. Stenmark, K.R., Meyrick, B., Galie, N., Mooi, W.J. and McMurtry, I.F. (2009) Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 297: L1013-L1032.
143. Subbaramaiah, K., Lin, D.T., Hart, J.C. and Dannenberg, A.J. ( 2001) Peroxisome proliferator-activated receptor gamma ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300. J Biol Chem 276: 12440-12448.
144. Sugawara, A., Uruno, A., Kudo, M., Ikeda, Y., Sato, K., Taniyama, Y. et al. (2002) Transcription suppression of thromboxane receptor gene by peroxisome proliferator-activated receptor-gamma via an interaction with Sp1 in vascular smooth muscle cells. J Biol Chem 277: 9676-9683.
145. Summer, R., Fiack, C.A., Ikeda, Y., Sato, K., Dwyer, D., Ouchi, N. et al. (2009) Adiponectin deficiency: a model of pulmonary hypertension associated with pulmonary vascular disease. Am J Physiol Lung Cell Mol Physiol 297: L432-L438.
146. Szanto, A. and Nagy, L. ( 2008) The many faces of PPARgamma: anti-inflammatory by any means? Immunobiology 213: 789-803.
147. Tallquist, M. and Kazlauskas, A. ( 2004) PDGF signaling in cells and mice. Cytokine Growth Factor Rev 15: 205-213.
148. Tesse, A., Al-Massarani, G., Wangensteen, R., Reitenbach, S., Martinez, M.C. and Andriantsitohaina, R. ( 2008) Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, prevents microparticle-induced vascular hyporeactivity through the regulation of proinflammatory proteins. J Pharmacol Exp Ther 324: 539-547.
149. Tong, H., Chen, W., Steenbergen, C. and Murphy, E. ( 2000) Ischemic preconditioning activates phosphatidylinositol-3-kinase upstream of protein kinase C. Circ Res 87: 309-315.
150. Tontonoz, P., Hu, E., Graves, R.A., Budavari, A.I. and Spiegelman, B.M. ( 1994) mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 8: 1224-1234.
151. Tuder, R.M., Cool, C.D., Geraci, M.W., Wang, J., Abman, S.H., Wright, L. et al. (1999) Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 159: 1925-1932.
152. Tuder, R.M., Groves, B., Badesch, D.B. and Voelkel, N.F. ( 1994) Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 144: 275-285.
153. Tuder, R.M. and Voelkel, N.F. ( 1998) Pulmonary hypertension and inflammation. J Lab Clin Med 132: 16-24.
154. Wang, C.H., Ciliberti, N., Li, S.H., Szmitko, P.E., Weisel, R.D., Fedak, P.W. et al. (2004) Rosiglitazone facilitates angiogenic progenitor cell differentiation toward endothelial lineage: a new paradigm in glitazone pleiotropy. Circulation 109: 1392-1400.
155. Wang, Q., Zhou, Y., Wang, X., Chung, D.H. and Evers, B.M. ( 2007) Regulation of PTEN expression in intestinal epithelial cells by c-Jun NH2-terminal kinase activation and nuclear factor-kappaB inhibition. Cancer Res 67: 7773-7781.
156. Wang, T.D., Chen, W.J., Cheng, W.C., Lin, J.W., Chen, M.F. and Lee, Y.T. ( 2006) Relation of improvement in endothelium-dependent flow-mediated vasodilation after rosiglitazone to changes in asymmetric dimethylarginine, endothelin-1, and C-reactive protein in nondiabetic patients with the metabolic syndrome. Am J Cardiol 98: 1057-1062.
157. Werner, N., Kosiol, S., Schiegl, T., Ahlers, P., Walenta, K., Link, A. et al. (2005) Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 353: 999-1007.
158. Wohlfert, E.A., Nichols, F.C., Nevius, E. and Clark, R.B. ( 2007) Peroxisome proliferator-activated receptor gamma (PPARgamma) and immunoregulation: enhancement of regulatory T cells through PPARgamma-dependent and -independent mechanisms. J Immunol 178: 4129-4135.
159. Xue, C. and Johns, R.A. ( 1995) Endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 333: 1642-1644.
160. Zaidi, S.H., You, X.M., Ciura, S., Husain, M. and Rabinovitch, M. ( 2002) Overexpression of the serine elastase inhibitor elafin protects transgenic mice from hypoxic pulmonary hypertension. Circulation 105: 516-521.
161. Zhang, L., Sheppard, O.R., Shah, A.M. and Brewer, A.C. ( 2008) Positive regulation of the NADPH oxidase NOX4 promoter in vascular smooth muscle cells by E2F. Free Radic Biol Med 45: 679-685.
162. Zhao, Y.D., Courtman, D.W., Ng, D.S., Robb, M.J., Deng, Y.P., Trogadis, J. et al. (2006) Microvascular regeneration in established pulmonary hypertension by angiogenic gene transfer. Am J Respir Cell Mol Biol 35: 182-189.
163. Zhu, Y., Kan, L., Qi, C., Kanwar, Y.S., Yeldandi, A.V., Rao, M.S. et al. (2000) Isolation and characterization of peroxisome proliferator-activated receptor (PPAR) interacting protein (PRIP) as a coactivator for PPAR. J Biol Chem 275: 13510-13516.